Anthem Biosciences IPO: Firm raises ₹1,016 crore from anchor investors

Anthem Biosciences has raised ₹1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription.

Some of the investors who participated in the anchor book are Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds, Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF, and Motilal Oswal MF, according to a BSE circular.

As per the circular, the company has allocated 1.78 crore equity shares to 60 funds at ₹570 apiece, which is the upper end of the price band. This aggregates the transaction size to ₹1,016 crore.

Anthem Biosciences, which is engaged in drug discovery, development, and manufacturing, will launch its ₹3,395 crore initial public offering (IPO) on July 14. The IPO will remain open for subscription till July 16. The IPO is a complete offer-for-sale of a total of 5.95 crore shares.

Incorporated in 2006, Anthem Biosciences is an innovation-driven contract research, development, and manufacturing organisation (CRDMO). Anthem Biosciences is one of the few companies in India with integrated new chemical entity (NCE) and new biological entity (NBE) capabilities across drug discovery, development, and commercial manufacturing.

As of March 31, 2025, the company had more than 550 customers across both the CRDMO and speciality ingredients businesses, spread over more than 44 countries, including the United States, European countries, and Japan. The top five customers collectively accounted for 70.92% of revenue from operations for FY25, with the largest customer contributing 24.22% of revenue.

Anthem Biosciences IPO aims to raise ₹3,395 crore through its public issue. The IPO is a complete offer-for-sale of over 5.95 crore shares.

The company has fixed the price band of the issue at ₹540 to ₹570 per share. The lot size, or the minimum bid quantity to apply for the issue, is 26 shares. This equates to a minimum investment amount of ₹14,820 per lot at the upper end of the price band for retail investors.

Anthem Biosciences has appointed JM Financial Limited as book-running lead managers of the IPO, while Kfin Technologies Limited is the registrar for the issue.

• IPO is a complete offer for sale: Net IPO proceeds will go to the selling shareholders of the company.

• Listing on stock exchanges: The company wants to achieve the benefits of listing its shares on the stock exchange.